Correlation between SPARC expression and efficacy of nab-paclitaxel for advanced gastric cancer refractory to fluoropyrimidine: An exploratory analysis of a phase II trial, CCOG1303

被引：0
|
作者：
Kobayashi, D. [1 ]
Enomoto, A. [2 ]
Mochizuki, Y. [3 ]
Matsui, T. [4 ]
Nakayama, H. [5 ]
Kawase, Y. [6 ]
Ishigure, K. [7 ]
Shikano, T. [8 ]
Torii, K. [9 ]
Kodera, Y. [1 ]
机构：
[1] Nagoya Univ, Grad Sch Med, Gastroenterol Surg, Nagoya, Aichi, Japan
[2] Nagoya Univ, Grad Sch Med, Pathol, Nagoya, Aichi, Japan
[3] Komaki Municipal Hosp, Dept Surg, Komaki, Japan
[4] Aichi Canc Ctr Hosp, Dept Surg, Okazaki, Aichi, Japan
[5] Natl Hosp Org, Dept Surg, Nagoya Med Ctr, Nagoya, Aichi, Japan
[6] Tosei Gen Hosp, Dept Surg, Seto, Japan
[7] Konan Kosei Hosp, Dept Surg, Konan, Japan
[8] Yokkaichi Municipal Hosp, Dept Surg, Yokaichi, Japan
[9] Nakatsugawa Municipal Gen Hosp, Dept Surg, Nakatsugawa, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
696P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II clinical trial of nab-paclitaxel plus cisplatin plus gemcitabine (NABPLAGEM) in patients with untreated advanced pancreatic cancer
    Jameson, Gayle S.
    Hosein, Peter J.
    Pierce, Erin
    Kamgar, Mandana
    Gordon, Michael S.
    Snyder, Courtney
    Roe, Denise J.
    Wertheim, Betsy C.
    Davey, Marina
    Barrett, Michael T.
    Von Hoff, Daniel D.
    Borazanci, Erkut
    CANCER MEDICINE, 2024, 13 (12):
  • [32] Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials
    Steffen Ormanns
    Michael Haas
    Sibylle Baechmann
    Annelore Altendorf-Hofmann
    Anna Remold
    Detlef Quietzsch
    Michael R Clemens
    Martin Bentz
    Michael Geissler
    Helmut Lambertz
    Stephan Kruger
    Thomas Kirchner
    Volker Heinemann
    Stefan Boeck
    British Journal of Cancer, 2016, 115 : 1520 - 1529
  • [33] Phase II trial of neoadjuvant chemotherapy with carboplatin and nab-paclitaxel in patients with triple negative locally advanced and inflammatory breast cancer
    Somlo, G.
    Chung, S.
    Frankel, P.
    Hurria, A.
    Koehler, S.
    Kruper, L.
    Mortimer, J. E.
    Paz, B.
    Robinson, K.
    Taylor, L.
    Vito, C.
    Waisman, J.
    Yeon, C.
    Yim, J.
    Yuan, Y.
    Tong, T.
    CANCER RESEARCH, 2016, 76
  • [34] Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials
    Ormanns, Steffen
    Haas, Michael
    Baechmann, Sibylle
    Altendorf-Hofmann, Annelore
    Remold, Anna
    Quietzsch, Detlef
    Clemens, Michael R.
    Bentz, Martin
    Geissler, Michael
    Lambertz, Helmut
    Kruger, Stephan
    Kirchner, Thomas
    Heinemann, Volker
    Boeck, Stefan
    BRITISH JOURNAL OF CANCER, 2016, 115 (12) : 1520 - 1529
  • [35] Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial
    Michel Ducreux
    Jaafar Bennouna
    Antoine Adenis
    Thierry Conroy
    Astrid Lièvre
    Fabienne Portales
    Julie Jeanes
    Li Li
    Alfredo Romano
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 9 - 16
  • [36] Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial
    Ducreux, Michel
    Bennouna, Jaafar
    Adenis, Antoine
    Conroy, Thierry
    Lievre, Astrid
    Portales, Fabienne
    Jeanes, Julie
    Li, Li
    Romano, Alfredo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (01) : 9 - 16
  • [37] Phase II Trial of Weekly Nab-Paclitaxel for Previously Treated Advanced Non-Small Cell Lung Cancer: KTOSG Trial 1301
    Sakata, Shinya
    Saeki, Sho
    Okamoto, Isamu
    Otsubo, Kohei
    Komiya, Kazutoshi
    Morinaga, Ryotaro
    Yoneshima, Yasuto
    Koga, Yuichiro
    Enokizu, Aimi
    Kishi, Hiroto
    Hirosako, Susumu
    Yamaguchi, Emi
    Aragane, Naoko
    Fujii, Shinji
    Harada, Taishi
    Iwama, Eiji
    Nakanishi, Yoichi
    Kohrogi, Hirotsugu
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S923 - S923
  • [38] A phase I and randomized phase II trial to evaluate the efficacy and safety of nab-paclitaxel (nab-P) in combination with gemcitabine (G) for the treatment of patients with ECOG 2 advanced pancreatic cancer (PDAC)
    Hidalgo, M.
    Pazo-Cid, R.
    Guillen-Ponce, C.
    Lopez, R.
    Vera, R.
    Reboredo, M.
    Munoz, A.
    Martinez de Castro, E.
    Diaz Beveridge, R.
    La Casta, A.
    Martin-Valades, J. I.
    Cubillo, A.
    Martinez-Galan, J.
    Ales, I.
    Sastre, J.
    Macarulla Mercade, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [39] Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group
    Katsaounis, Panagiotis
    Kotsakis, Athanasios
    Kentepozidis, Nikolaos
    Polyzos, Aris
    Bakogeorgos, Marios
    Koinis, Filippos
    Vamvakas, Lambros
    Vardakis, Nikolaos
    Kalbakis, Kostas
    Boukovinas, Ioannis
    Varthalitis, Ioannis I.
    Prinarakis, Efthimios
    Georgoulias, Vassilis
    Souglakos, John
    ANNALS OF GASTROENTEROLOGY, 2018, 31 (01): : 65 - 70
  • [40] Glucocorticoid receptor expression and activity in a phase II ovarian cancer trial of the glucocorticoid receptor modulator relacorilant in combination with nab-paclitaxel
    Lorusso, D.
    Greenstein, A. E.
    Wadekar, S. A.
    Tudor, I. C.
    Hunt, H. J.
    Guyer, B.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S784 - S785
12345